Allergan, Inc.

  • A New Migraine Therapy That Can Address a Major Demand

    By Kanak Kanti - July 9, 2013 | Tickers: AGN, LLY, PATH

    Note: This article has been amended to better reflect Levadex's position in this market. 

    One-fourth of all migraine patients suffer nasty side effects from the market's dominant migraine-fighting treatments. Now, a new, convenient inhaled version of one of the few drugs these patients can use -- previously only available as an IV administered by doctors -- could lead to big benefits for Allergan (NYSE: AGN).

    The $4 billion global migraine more »

  • Is This Biotech for Sale?

    By Sherrie Stone - July 5, 2013 | Tickers: AGN, LLY, SPPI

    For the last five years, Spectrum Pharmaceuticals (NASDAQ: SPPI) CEO Rajesh Shrotriya has always insisted that Spectrum was an acquisitive company, rather than “for sale”. But after a rough 2013, and many investors doubting the company’s future, the company might be exploring a sale.

    The Run-Down

    Before you Spectrum bulls get too excited, I’m not suggesting a $1 billion buyout or a 100% premium. Instead, I'd predict more »

  • Why Blackrock Advisors doubled its stake in this company?

    By Aubrey Tabuga - July 5, 2013 | Tickers: AGN

    Blackrock Advisors almost doubled its stake in Allergan (NYSE: AGN) in the latest quarter. Is it worth it? The FDA’s recent announcement over establishing bioequivalence for its Restasis has fueled the recent sell-off of Allergan’s stock. The draft guidance says FDA may not require human clinical trials to be done by a generic manufacturer to produce a version of Allergan’s Restasis. I believe that despite this, Allergan more »

  • For Allergan Shareholders, Will it Be Dry Eyes or Tears of Joy?

    By John Macris - June 28, 2013 | Tickers: AGN, MRK, PFE

    On June 24, the Food and Drug Administration issued “bioequivalence recommendations” for 15 active ingredients used in prescription medications. Bioequivalence is a pharmacology term used to compare the properties of two drugs with an identical active ingredient, most likely a brand-name drug and its generic equivalent.

    One of the new guidelines issued on Monday is for cyclosporine, the active ingredient in blockbuster drug Restasis developed by Allergan Inc. (NYSE: AGNmore »)

  • Three Stocks To Short

    By Jayson Derrick - June 25, 2013 | Tickers: AGN, ABX, DD, DOW

    After a strong bull run in 2013, it appears that the markets are set to reverse and enter bear territory. Investors can still profit by shorting stocks that are operating in an environment that is detrimental to their business.

    Global macro environment is not favorable

    Dow Chemical Co (NYSE: DOW) is seeing greater Q2 headwinds than many had assumed at the beginning of the quarter, due to a global macro more »

  • What Miss Utah Should Have Said

    By Lee Samaha - June 20, 2013 | Tickers: AGN, DLTR, PETM, VRNT, WFM

    I would have voted for Miss Utah. Not only did I find her the most attractive but she also gave a pretty coherent answer to a question which appeared to be come pre-loaded with a rather poorly thought out line of argument.

    It gets worse. Most of the press following the famous question and answer session in the Miss USA pageant hasn’t managed to give a better answer to more »

  • What’s Next For This Biotech?

    By Sherrie Stone - June 11, 2013 | Tickers: ACAD, AGN, AZN

    ACADIA Pharmaceuticals’ (NASDAQ: ACAD) 1,100% gain makes it one of the best performing stocks in the market. This rally began after its Parkinson’s disease drug Pimavanserin produced a positive outcome in its Phase III trial.

    In particular, Pimavanserin had no negative impact on motor function and significantly reduced psychotic episodes compared to placebo. The drug’s likelihood for approval is now all but a guarantee, and investors are more »

  • What I Bought and Sold This Quarter

    By Lee Samaha - June 8, 2013 | Tickers: AGN, CTXS, CL, NTAP, SHW

    In the end, numbers are just numbers and while they are an indispensable part of an investor's self-assessment, they do not always reveal the full details. For example, my last month closed with a negligible loss but the truth is, I started the month notably down after two profit warnings on the last day of April. In retrospect, it was a pleasing month and I think there are some more »

  • 3 Keys to Acadia's Future

    By Brandy Betz - June 3, 2013 | Tickers: ACAD, AGN

    Acadia Pharmaceuticals (NASDAQ: ACAD) had a busy couple of months. The new member of the Nasdaq Biotechnology Index recently completed a $150 million public offering to help push lead drug candidate pimavanserin, a treatment for Parkinson’s disease psychosis, or PDP.

    In April, Acadia shares soared over 50% when the company filed an accelerated new drug application for pimavanserin after talks with the Food and Drug Administration. The pipeline’s more »

  • Valeant is Expanding its Eye Care Business

    By Anh HOANG - May 30, 2013 | Tickers: AGN, NVS, VRX

    The pharmaceutical industry is getting hotter with increasing M&A activities. Recently, Valeant Pharmaceuticals (NYSE: VRX) agreed to buy out Bausch + Lomb for around $8.7 billion in cash, including $4.2 billion used to pay the target’s debt. Right after the announcement, Valeant jumped more than 13% on the market to nearly $84.50 per share, reaching its all-time high.

    Strategic eye care acquisition

    Bausch + Lomb, the global more »

  • Should These Drug Companies Continue to Pay a Dividend?

    By Chris Hodge - May 24, 2013 | Tickers: AGN, RDY, NVO

    Editor's Note: The article has been modified to better describe the current companies' dividend arrangements.

    Even a hardcore dividend addict such as I will admit that there are times when a company should hold off on paying a dividend. The following is an examination of a few companies in the drug manufacturing sector and my conclusions about their dividend arrangements. In short, should these companies continue to pay dividends more »

  • Why This Stock's Crash is a Buying Opportunity

    By Lee Samaha - May 13, 2013 | Tickers: AGN, NVO, REGN, VRX

    It’s been a varied reporting season with a general uptrend in markets accompanying more than a few profit warnings. If you’ve been holding some of these names before the disappointments then it has been painful. The good news is that these situations can create buying opportunities. I think Allergan (NYSE: AGN) is a case in point, and here is why.

    Allergan’s Outlook

    It was almost a tale more »

  • Should We Get Bullish on This Fast Growing Healthcare Company?

    By Anh HOANG - May 10, 2013 | Tickers: AGN, JNJ, NVS

    Allergan (NYSE: AGN) has been consistently increasing on the market since the market bottom, from nearly $32 per share in November 2008 to more than $116 per share in the middle of April 2013. However, Allergan has experienced a lot of recent volatilty, and now is near $105. The company is in the portfolio of several successful investors including Joel Greenblatt and Jim Simons. Should investors consider Allergan at its more »

  • Key Earnings this Week

    By Lee Samaha - May 2, 2013 | Tickers: AGN, FB, MAS, PFE

    It’s another big week for earnings and by now investors will have formulated a thesis on the first quarter. That thesis will be put to the test this week. In my view there are some clear signs that there was a bit of caution over discretionary spending among corporations. Will it continue?

    As the weeks go by, let's recall that companies will get a bit more data on more »

  • Scared of a Market Fall? Watch These Defensive Growth Stocks

    By Lee Samaha - April 29, 2013 | Tickers: AGN, CHD, PRGO, COO, TJX

    The market turbulence in April has left many if whether we are headed for another spring sell off. I have no opinion on this, per se, but what I do know is that it always makes sense for investors to try and be diversified. So if you are worried about the economy or just looking to create a balanced portfolio, the following stocks should be of interest.

    Defensive growth

    I more »

  • Possible Synergies in This Buyout

    By Mike Thiessen - April 4, 2013 | Tickers: AGN, OMPI, VRX

    Investors have greeted the recent announcement that Valeant Pharmaceuticals (NYSE: VRX) and Obagi Medical Products (NASDAQ: OMPI) with enthusiasm. Structured as a Valeant buyout of Obagi, the deal offers a handsome premium for the medical company and provides further evidence that the latest wave of pharmaceutical consolidation has not yet peaked. Although this transaction does not have the same heft as some of the industry's other recent high-profile mergers more »

  • Possible Synergies in This Buyout

    By Mike Thiessen - April 4, 2013 | Tickers: AGN, OMPI, VRX

    Investors are enthusiastic about the recent merger announcement between Valeant Pharmaceuticals (NYSE: VRX) and Obagi Medical Products (NASDAQ: OMPI).

    Structured as a Valeant buyout of Obagi, the deal offers a handsome premium for the medical company and provides further evidence that the latest wave of pharmaceutical consolidation has not yet peaked. Although this transaction does not have the same heft as some of the industry's other recent high-profile mergers more »

  • Why these Large-Cap Stocks Need to be Bought Right Now

    By Shweta Dubey - March 20, 2013 | Tickers: AGN, AME, AON

    As the market pushes towards new highs, it’s time to look for large-cap stocks with solid fundamentals. With a better established business presence, these companies are less prone to uncertainties. Though their business growth rate may not be too high, that is offset by their stability in profits. These stocks are beneficial for those investors who are unwilling to take high levels of risk, and also to those who more »

  • 3 Health Stocks that Look Pretty

    By Alex Bastardas - March 18, 2013 | Tickers: ALGN, AGN, CYNO

    Sales growth in the beauty, personal care, and aesthetic treatment market in the United States doubled the average consumer spending rate growth in 2011 and in 2012. This year will probably not be an exception. In today's image-driven society, people are willing to spend significant amounts of money to look their best. And it's not just women - men are also jumping on the bandwagon, and so are foreign more »

  • Invest in the Spending Trends of the Wealthy

    By Lee Samaha - March 10, 2013 | Tickers: AGN, SAM, LULU, MYGN, WFM

    I have a quick trivia question. What share of total US net worth does the bottom 60% of US citizens (ranked by net worth) hold? The answer is just 4.2%, while the top 5% of US citizens (again ranked by net worth) owns nearly 62%.

    Now consider an average superstore in an average mall (such a thing doesn’t actually exist, but assume it does), and accept that spending more »

  • Page 1 of 3